PriceTargets.com logo

Black Diamond Therapeutics - BDTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.25
  • Forecasted Upside: 131.13%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$5.30 As of 04/18/2024 05:34 PM ET
▼ -0.4 (-7.02%)

This chart shows the closing price for BDTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Black Diamond Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BDTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BDTX

Analyst Price Target is $12.25
▲ +131.13% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Black Diamond Therapeutics in the last 3 months. The average price target is $12.25, with a high forecast of $16.00 and a low forecast of $10.00. The average price target represents a 131.13% upside from the last price of $5.30.

This chart shows the closing price for BDTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Black Diamond Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/23/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/19/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/19/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/8/2024WedbushBoost TargetOutperform ➝ Outperform$10.00 ➝ $16.00Low
3/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$11.00 ➝ $12.00Low
3/13/2024WedbushReiterated RatingOutperform ➝ Outperform$10.00Low
11/22/2023HC WainwrightReiterated RatingBuy ➝ Buy$11.00Low
9/12/2023WedbushReiterated RatingOutperform ➝ Outperform$10.00Low
7/14/2023Piper SandlerInitiated CoverageOverweight$11.00Low
6/29/2023Stifel NicolausUpgradeHold ➝ Buy$2.00 ➝ $10.00Low
6/28/2023HC WainwrightUpgradeNeutral ➝ Buy$11.00Low
6/27/2023WedbushUpgradeNeutral ➝ Outperform$10.00Low
3/29/2022WedbushDowngradeOutperform ➝ Neutral$4.00Medium
3/22/2022HC WainwrightDowngradeBuy ➝ NeutralMedium
3/18/2022Stifel NicolausLower TargetHold$10.00 ➝ $4.00High
9/29/2021Stifel NicolausInitiated CoverageHold$10.00High
8/18/2021WedbushLower TargetOutperform$48.00 ➝ $22.00High
8/17/2021Berenberg BankReiterated RatingBuy$34.00High
3/26/2021HC WainwrightReiterated RatingBuy$53.00Low
1/6/2021WedbushInitiated CoverageOutperform$45.00N/A
11/24/2020Berenberg BankInitiated CoverageBuy$58.00Medium
8/12/2020HC WainwrightReiterated RatingBuy$53.00High
5/4/2020HC WainwrightInitiated CoverageBuy$53.00Medium
2/24/2020CowenInitiated CoverageOutperformHigh
2/24/2020Jefferies Financial GroupInitiated CoverageBuy$47.00High
2/24/2020JPMorgan Chase & Co.Initiated CoverageOverweight$42.00High
(Data available from 4/18/2019 forward)

News Sentiment Rating

1.02 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
10/21/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2023
  • 4 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2023
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2024
  • 7 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2024
  • 6 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2024

Current Sentiment

  • 6 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Black Diamond Therapeutics logo
Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $5.30
Low: $5.13
High: $5.72

50 Day Range

MA: $4.84
Low: $3.78
High: $5.74

52 Week Range

Now: $5.30
Low: $1.43
High: $6.85

Volume

1,861,848 shs

Average Volume

591,206 shs

Market Capitalization

$274.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.64

Frequently Asked Questions

What sell-side analysts currently cover shares of Black Diamond Therapeutics?

The following sell-side analysts have issued reports on Black Diamond Therapeutics in the last twelve months: HC Wainwright, Piper Sandler, Stifel Nicolaus, and Wedbush.
View the latest analyst ratings for BDTX.

What is the current price target for Black Diamond Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Black Diamond Therapeutics in the last year. Their average twelve-month price target is $12.25, suggesting a possible upside of 131.1%. Wedbush has the highest price target set, predicting BDTX will reach $16.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $10.00 for Black Diamond Therapeutics in the next year.
View the latest price targets for BDTX.

What is the current consensus analyst rating for Black Diamond Therapeutics?

Black Diamond Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BDTX will outperform the market and that investors should add to their positions of Black Diamond Therapeutics.
View the latest ratings for BDTX.

What other companies compete with Black Diamond Therapeutics?

Other companies that are similar to Black Diamond Therapeutics include Fennec Pharmaceuticals, Monte Rosa Therapeutics, Metagenomi, Sutro Biopharma and Coherus BioSciences. Learn More about companies similar to Black Diamond Therapeutics.

How do I contact Black Diamond Therapeutics' investor relations team?

Black Diamond Therapeutics' physical mailing address is 139 MAIN STREET, CAMBRIDGE MA, 02142. The company's listed phone number is 617-252-0848 and its investor relations email address is [email protected]. The official website for Black Diamond Therapeutics is www. blackdiamondtherapeutics.com. Learn More about contacing Black Diamond Therapeutics investor relations.